Last reviewed · How we verify
NCT03942068
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
Status unknown
Phase 2
Last updated 8 May 2019
What this trial tests
Phase 2 trial testing albumin-bound paclitaxel in Ovarian Cancer in 35 participants. Status unknown.
Timeline
1 September 2019
Primary endpoint
1 September 2020
1 September 2020
30 December 2020
Quick facts
| Lead sponsor | Henan Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 1 September 2019 |
| Primary completion | 1 September 2020 |
| Estimated completion | 30 December 2020 |
Drugs / interventions tested
- albumin-bound paclitaxel — full drug profile →
- Apatinib (Apatinib) — full drug profile →
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Henan Cancer Hospital
Who can join
Adults 18 to 70, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study was designed to evaluate the efficacy and safety of apatinib with albumin-bound paclitaxel in patients with platinum-resistant recurrent ovarian cancer.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy.
Yang Y, Yang Y, Yang J, Zhao X, et al · · 2020 · cited 168× · PMID 32850861 · DOI 10.3389/fcell.2020.00758 -
Nanomedicine of tyrosine kinase inhibitors.
Smidova V, Michalek P, Goliasova Z, Eckschlager T, et al · · 2021 · cited 24× · PMID 33408767 · DOI 10.7150/thno.48662 -
Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.
Gralewska P, Gajek A, Marczak A, Rogalska A. · · 2024 · cited 21× · PMID 39125873 · DOI 10.3390/ijms25158304 -
Treatment of ovarian cancer: From the past to the new era (Review).
Alrosan K, Alrosan AZ, Heilat GB, Alrousan AF, et al · · 2025 · cited 9× · PMID 40535104 · DOI 10.3892/ol.2025.15130 -
Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy.
Jampilek J, Kralova K. · · 2022 · cited 8× · PMID 36559200 · DOI 10.3390/pharmaceutics14122706 -
Nanotherapeutic Formulations for the Delivery of Cancer Antiangiogenics.
Ultimo A, Jain A, Gomez-Gonzalez E, Alex TS, et al · · 2025 · cited 1× · PMID 40184281 · DOI 10.1021/acs.molpharmaceut.4c00822
Verify or expand the search:
- PubMed search for NCT03942068
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of albumin-bound paclitaxel
Trials testing the same drug.
- NCT06177522 — Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07019181 — Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma · Phase 2 · not yet recruiting
- NCT06791148 — Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Canc · Phase 2 · recruiting
- NCT05316376 — Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoa · Phase 2 · unknown
- NCT04459611 — Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） · Phase 2 · unknown
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Henan Cancer Hospital trials
Trials by the same sponsor.
- NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
- NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
- NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
- NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
- NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03942068 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
- Last refreshed: 8 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03942068.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing